A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas
Crossref DOI link: https://doi.org/10.1186/2051-1426-2-S3-P73
Published Online: 2014-11-06
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Goswami, Trishna
Canelos, Paola
Parikh, Radhika
Article History
First Online: 6 November 2014